Marshall Wace LLP Sells 683,619 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Marshall Wace LLP lessened its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 45.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 807,172 shares of the company's stock after selling 683,619 shares during the quarter. Marshall Wace LLP owned about 1.19% of Perspective Therapeutics worth $2,575,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vontobel Holding Ltd. acquired a new stake in Perspective Therapeutics in the fourth quarter worth about $51,000. Barclays PLC raised its position in shares of Perspective Therapeutics by 587.9% during the 3rd quarter. Barclays PLC now owns 114,075 shares of the company's stock worth $1,523,000 after buying an additional 97,493 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Perspective Therapeutics by 41.3% in the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company's stock worth $83,000 after acquiring an additional 7,627 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Perspective Therapeutics by 24.1% in the third quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company's stock valued at $333,000 after acquiring an additional 4,844 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Perspective Therapeutics by 12.5% during the third quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company's stock valued at $15,546,000 after acquiring an additional 129,654 shares during the period. Institutional investors own 54.66% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CATX. Scotiabank assumed coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 target price for the company. Truist Financial cut their price objective on Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating for the company in a report on Monday, April 7th. Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Monday, March 31st. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $12.75.

Perspective Therapeutics Trading Up 6.3 %

NYSE CATX traded up $0.16 on Friday, hitting $2.63. 145,389 shares of the stock were exchanged, compared to its average volume of 1,022,656. The company's 50-day moving average price is $2.28 and its two-hundred day moving average price is $4.44. Perspective Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $19.05.

Insider Transactions at Perspective Therapeutics

In related news, CEO Johan M. Spoor bought 22,026 shares of the business's stock in a transaction on Friday, March 28th. The stock was bought at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the transaction, the chief executive officer now directly owns 59,383 shares in the company, valued at $133,017.92. This represents a 58.96 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert F. Williamson III purchased 22,192 shares of the stock in a transaction dated Friday, March 28th. The shares were bought at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the acquisition, the director now owns 70,837 shares in the company, valued at $160,799.99. This represents a 45.62 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 115,696 shares of company stock valued at $256,344 over the last quarter. Company insiders own 3.52% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.